Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Study Information
Alliance Study ID: NCCTG-N9975
NCT Study ID (ClinicalTrials.gov): NCT00005610
Disease or Cancer Type: Melanoma & Skin Cancers
Alliance Study Chair: Svetomir Markovic, MD, PhD
Status: COMPLETED
Study Description
RATIONALE: Colony-stimulating factors, such as sargramostim, may help the body’s immune system to kill cancer cells. Giving sargramostim in different ways may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of sargramostim given as a breathing treatment for treating patients who have melanoma that is metastatic to the lung.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information